| 肺动脉高压药物治疗进展 |
| |
| 引用本文： | 黄震华. 肺动脉高压药物治疗进展[J]. 中国新药与临床杂志, 2006, 25(1): 66-69 |
| |
| 作者姓名： | 黄震华 |
| |
| 作者单位： | 上海交通大学医学院附属第九人民医院,心血管病研究室,上海,200011 |
| |
| 摘 要： | 肺动脉高压分为原发性和继发性肺动脉高压。肺动脉高压具有药物治疗效果和预后差的特点。血管内皮功能减退与肺动脉高压的发生发展具有极其密切的关系。前列环素类似物、内皮素受体拮抗药等是新开发的有效治疗肺动脉高压的药物。
|
| 关 键 词： | 一氧化氮 内皮缩血管钛类 内皮 血管 肺动脉高压 前列环素 |
| 文章编号： | 1007-7669（2006）01-0066-04 |
| 收稿时间： | 2005-07-14 |
| 修稿时间： | 2005-07-142005-11-07 |
Advances in drug treatment of pulmonary hypertension |
| |
| HUANG Zhen-hua. Advances in drug treatment of pulmonary hypertension[J]. Chinese Journal of New Drugs and Clinical Remedies, 2006, 25(1): 66-69 |
| |
| Authors: | HUANG Zhen-hua |
| |
| Abstract: | Pulmonary hypertension is divided into primary pulmonary hypertension and secondary pulmonary, hypertension. Pulmonary hypertension has the characteristics of poor effects of drug treatment and poor prognosis. Vascular endothelial dysfunction has close relation ship with the development of pulmonary hypertension and prostacyelin analogue, endothelin receptor antagonists are new drug for the treatment. |
| |
| Keywords: | nitrie oxide endothelins endothelium, vascular pulmonary hypertension prostacyclin |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
